TotalSeq™-D Acute Myeloid Leukemia Antibody Cocktail
AML is a highly heterogeneous disease where both clonal evolution and immunophenotypic shifts, including lineage-defining CD markers and surface antigens, influence therapy response and relapse. For the first time, single-cell DNA and protein panels can be combined to simultaneously assess clonal architecture and immunophenotypic diversity, providing deeper insights into AML biology and therapeutic resistance.
Panel Details
TotalSeq™-D Acute Myeloid Leukemia Antibody Cocktail
The TotalSeq-D Acute Myeloid Leukemia Antibody Cocktail has been designed to react with 17 unique cell surface antigens, including key biomarkers to aid in immunophenotypic characterization of AML cells. The antibodies in the cocktail are provided at optimized concentrations to provide a ready-to-use solution.
View and download panel content and coordinates using Tapestri Designer
Have novel applications?
Our team of experts is ready to support requests for custom oligo-conjugated antibodies from BioLegend. Tell us about your targets of interest.
